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Abstract: In the last decade, hydroxycinnamic acids (HCA) have gained increasing attention from researchers due to their 
antioxidant potential. The aim of this study was to examine in detail the impact of dietary HCA on particular types of 
P450 and also selected phase II and antioxidant enzymes in Wistar rat. HCA (10 μM/kg/day, i.p.) was administered for ten 
continuous days. Examination of the activities and mRNA and protein levels revealed that CYP2B, 2C6 and 3A enzyme 
activities were not altered significantly, with Western blot and qRT-PCR results corroborating this result. While treatment 
with HCA led to a significant reduction in CYP1A1/CYP1A2-associated enzyme activities, CYP1A1 protein, and mRNA 
levels were found to be unchanged. Aromatase (CYP19) activity, as well as protein and mRNA levels, were significantly 
reduced with HCA treatment. On the other hand, the NAD(P)H:quinone oxidoreductase 1 (NQO1), catalase (CAT), glu-
tathione peroxidase (GPx) and glutathione S-transferases (GSTs) activities were increased significantly. Also, HCA treat-
ment significantly increased the GST-mu and GST-theta mRNA levels. These observations may be of importance given the 
potential use of HCA as a chemopreventive and as an anticancer agent
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INTRODUCTION
Dietary polyphenols have received significant con-
sideration in last decades. They constitute a heteroge-
neous group of compounds, including phenolic acids, 
flavonoids, tannins, coumarins and lignans, among 
others [1]. Prolonged utilization of a polyphenol-rich 
diet has been demonstrated to be protective against 
cardiovascular and neurodegenerative ailments, dia-
betes and cancer [2-6]. Phenolic acids have antioxidant 
action as chelators and free radical scavengers with 
specific effect over hydroxyl and peroxyl radicals, su-
peroxide anions and peroxynitrites [6]. They are made 
up of hydroxycinnamic and hydroxybenzoic acids.
Hydroxycinnamic acids (HCAs) are a subgroup 
of phenolic acids with a widespread distribution in 
plants. They are abundant in tea leaves, coffee, differ-
ent organic products, vegetables and whole grains [1]. 
Cytochrome P450s (CYP450), which are driving phase 
I enzymes, have an essential part in the metabolic acti-
vation or detoxification of medications in addition to 
dietary constituents and environmental compounds 
[7-9]. Accordingly, the balance of this protein frame-
work can impact the metabolism of xenobiotics, cre-
ating impacts of pharmacological and toxicological 
significance. Various natural flavonoids have been 
demonstrated to alter the CYP450 framework, includ-
ing the induction of particular CYP isozymes, and 
the activation or inhibition of these catalysts [10,11]. 
Among these P450s, the CYP1A, CYP2B, CYP2C and 
CYP3A subfamilies have received much consideration 
due to their capacity to metabolize different pharma-
ceuticals and their role in chemical carcinogenesis 
[12-14]. CYP19 (aromatase) is the pivotal catalyst of 
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estrogen biosynthesis and increased expression of aro-
matase has been seen in breast cancer [15,16]. 
Phase II biotransformation responses for the most 
part serve as a detoxifying step in xenobiotic metabo-
lism. Thus, another conceivable system for the chemo-
protective and cell reinforcement impacts of phenolic 
acids may include the prompting of phase II and an-
tioxidant enzymes [17-20]. Glutathione S-transferases 
(GSTs) are a complex multigene family of enzymes 
[21] that assume a critical function in detoxification 
by conjugating glutathione with an extensive number 
of electrophilic metabolites formed from a diverse set 
of xenobiotics, including cancer-causing agents, toxins, 
and medications. NAD(P)H:quinone oxidoreductase 1 
(NQO1) forestalls quinine redox cycling and lowers the 
levels of electrophilic quinines [22]. Therefore, the in-
duction of GST and NQO1 by phenolic acids is poten-
tially connected with tumor chemopreventive impacts.
Recently, we have reported on the modulatory 
activity of HCA on carcinogen activating proteins in 
HepG2 cell lines [23]. Therefore, the present study at-
tempted to examine further the general synchronous 
changes following in vivo treatment of rodents with 
HCA, for this reason, changes in the activity, mRNA, 
and protein levels of particular hepatic P450s, phase 
II, and antioxidant enzymes were studied. To our 
knowledge, this is the first report of the in vivo im-
pact of HCA on drug-metabolizing cytochrome P450 
enzymes, examined by studying the changes in their 
mRNA and protein levels and activities in the rat.
MATERIALS AND METHODS
Animals and treatment
Male Wistar rats, around 12 weeks old and weighing 
200-250 g, were supplied by the University Animal 
House. They were housed in small confines at an 
encompassing temperature of 22±1 °C, with a 12 h 
light/dark cycle, and a standard pellet diet and refined 
water were accessible without restriction. Every single 
trial with the animals was performed under suitable 
administrations with veterinary services within the 
authorized projects.
After being acclimatized for a week, the rats were 
randomized and divided into two groups: HCA was 
administered to 15 rats at a dose of 10 µM/kg (dis-
solved in 10% dimethyl sulfoxide (DMSO)); the con-
trol (10) rats received the vehicle (10% DMSO). The 
animals were treated intraperitoneally (i.p.) for 10 
consecutive days. At the end of the experimental pe-
riod and following 16 h of fasting, blood was collected 
by heart puncture, and the rats were killed. The livers 
were removed, rinsed with cold physiological saline 
and stored at -80°C until analyzed.
Preparations of S1.5, cytosolic and microsomal 
fractions
Tissues were homogenized in homogenization 
solution (1.15% potassium chloride containing 
3 mM ethylenediaminetetraacetic acid, 0.5 mM 
4-amidinophenylmethyl-sulphonylfluoride, 0.3 mM 
ε-aminocaproic acid, 0.15 mM butylated hydroxy-
toluene, 0.025% Triton X-100) using a tissue homog-
enizer with a Teflon pestle at 4°C. Subcellular fractions 
(S1.5, cytosolic and microsomal) of rat tissues were 
prepared by standard differential centrifugation with 
calcium aggregation as described [24]. The amount 
of protein in individual fractions was measured using 
bicinchoninic acid [25] with bovine serum albumin 
as the standard. 
Enzyme assays
Serum aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) activities were determined 
with an autoanalyzer using audit diagnostic reagents 
for AST and ALT. The microsomal cytochrome P450-
dependent aminopyrene N-demethylase (APND), 
erythromycin N-demethylase (ERND), caffeine N-
demethylase (C3ND), ethylmorphine N-demethylase 
(EmND) and benzphetamine N-demethylase (BPND) 
activities were determined by measuring the quantity 
of formaldehyde formed according to the method of 
Nash [26] and modified by Cochin and Axelrod [27]. 
Ethoxyresorufin-O-deethylase (EROD), methoxyreso-
rufin O-demethylase (MROD), benzyloxyresorufin 
O-dealkylase (BROD), and pentyloxyresorufin O-
dealkylase (PROD) activities were assayed as de-
scribed by Sen and Arinc [28]. Dibenzylfluorescein 
O-debenzylase (DBFOD) activity was assayed accord-
ing to the method of Kragie [29] as optimized by Celik 
et al. [16]. GST activities were assayed as described 
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bz Habig et al. [30]. Catalase (CAT) and glutathione 
peroxidase (GPx) activities were determined by the 
methods of Abei [31] and Paglia and Valentine [32], 
respectively. NQO1 enzyme activity was determined 
according to the method of Ernster [33] as modified 
by Karakurt and Adali [34].
Gel electrophoresis and Western blotting
SDS-PAGE and Western blotting were performed as 
described [28]. Briefly, 120-μg protein samples were 
separated on 8.5% polyacrylamide gels using the dis-
continuous buffer system of Laemmli [35]. Proteins 
were transferred to a nitrocellulose membrane by the 
iBlot dry blotting system (20 V, 12 min), using iBlot 
gel transfer stacks. Following transfer, the membranes 
were blocked using 5% non-fat dry milk in TBST (20 
mM Tris-HCl, pH 7.4, 400 mM NaCl and 0.1% (v/v) 
Tween 20) for 60 min and incubated with mouse poly-
clonal anti-rat CYP1A1, CYP2B, CYP2C6, CYP3A1 
or CYP19 antibodies (diluted 1:1000 in blocking so-
lution) for 120 min at room temperature. The mem-
branes were then washed with TBST (Tris-buffered 
saline with Tween 20) (3 x 5 min), incubated with 
the secondary antibody (HRP-conjugated anti-rabbit 
IgG at a 1:5000 or 1:10000 dilution) for 60 min and 
again washed with TBST (3 x 5 min). Proteins were 
detected using SuperSignal® West Pico Chemilumi-
nescent Substrate (Pierce, Rockford, IL, USA), and 
bands were visualized and recorded using GelQuant 
Image Analysis Software in a DNR LightBIS Pro Im-
age Analysis System (DNR Bio-Imaging Systems Ltd. 
Jerusalem, Israel). Protein bands were quantified using 
Scion Image Version Beta 4.0.2 software.
RNA isolation and qRT-PCR of CYP mRNAs
Total RNA was extracted from 100 mg of rat liver 
using Trizol reagent. Extracted RNA was quantified 
spectrophotometrically at 260/280 nm, and the in-
tegrity was checked using 1% agarose gel. For cDNA 
synthesis, 2.5 μg of RNA was incubated at 70°C for 
10 min with 0.5 μg of oligo(dT). After 5 min on ice, 
50 U Moloney murine leukemia virus reverse tran-
scriptase, 1 mM dNTPs and 5X reaction buffer were 
added to the previous mixture and incubated at 42°C 
for 60 min. The reaction was stopped by heating at 
70°C for 10 min, and the cDNA was stored at -80°C 
for further analysis.
The qRT-PCR assay was performed using gene-
specific primers. The oligo sequences used as forward 
and reverse primers for rat CYP450 isozymes were 
based on those reported in Agus et al. [36]. Glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) served as 
a housekeeping gene. PCR amplification was performed 
using Power SYBR Green PCR master mix (Roche Ap-
plied Science, Basel, Switzerland) and 500 nmol/L of 
forward and reverse primers for each gene for which 
the final primer concentration was 125 nmol/L each. 
Quantitative PCR was done using a Light Cycler 1.5 In-
strument (Roche Applied Science, Basel, Switzerland). 
The PCR conditions were as follows: DNA polymerase 
activation at 95°C for 15 min, followed by 45 cycles at 
95°C for 10 s, 54-57°C annealing (depending on the 
gene) for 5 s and 72°C for 30 s. All gene analyses were 
done at least three times with triplicates. 
Statistical analysis
Statistical analyses were carried out utilizing the Minit-
ab 13 statistical software bundle. (Minitab, Inc., State 
College, PA, USA). All outcomes were expressed as 
means including their standard error of means (SEMs). 
Following normalization, the data can be used for de-
termining the magnitude of effect due to the treat-
ment. In the current literature this has typically been 
achieved by applying a Student’s t-test, and P<0.05 was 
chosen as the level of statistical significance.
RESULTS
Control and treated rats demonstrated no critical con-
trasts in alimenting or body weight (data not given) 
after i.p. treatment with HCA. As indicated in Table 1, 
blood serum AST and ALT activities were not changed 
when compared with the control rats.
As can be seen in Table 2, hepatic 1A1-associ-
ated EROD and 1A2-associated MROD and C3ND 
activities were decreased by 23%, 13% and 13% in the 
HCA-treated rats, respectively when compared to the 
control rats. CYP2B-associated BPND, EmND, BROD 
and PROD activities were not changed significantly in 
the HCA-treated rats as compared to the control ani-
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mals (Table 2). CYP19-associated DBFOD activities 
of the control and HCA-treated rats are also given in 
Table 2. DBFOD activities were decreased by 16% in 
HCA-treated animals (P<0.05). The effect of the HCA 
on CYP2C6-associated APND and CYP3A-associated 
ERND is presented in Table 2. HCA treatment did not 
change APND and ERND activities significantly as 
compared to the controls. 
As can be seen in Table 2, GST-1-chloro-2,4-
dinitrobenzene (GST-CDNB), GST-1,2-dichloro-4-
nitrobenzene (GST-DCNB) and GST-ethacrynic acid 
(GST-EA) activities were increased by 20%, 46% and 
59% (P<0.05), respectively. Furthermore, treatment of 
rats with HCA caused 35%, 42% and 32% increases in 
NQO1, CAT and GPX activities, respectively, when 
compared to the control values (Table 2).
Catalytic activities were by and large predictable 
with the protein levels of related CYP isoforms in rat 
liver microsomes that were prepared from control 
and HCA-treated rats (Fig. 1A). The densitometric 
scanning of Western blot results demonstrated that 
hepatic CYP1A, CYP2B, CYP2C and CYP3A were not 
significantly altered in the HCA-treated rats in respect 
to the control animals, while the CYP19 protein level 
was decreased (42%) (Fig. 1B). 
The effect of HCA on the mRNA levels of CYP 
isozymes was also determined in this study. The rela-
tive CYP1A, CYP2B, CYP2C and CYP3A mRNA lev-
els were not changed significantly in the HCA-treated 
rats compared to the control animals (Fig. 2). How-
ever, the CYP19 mRNA level was decreased by 47% in 
HCA-treated rats (Fig. 2). In addition, we established 
that HCA treatment significantly increased GST-mu 
and GST-theta mRNA levels in the liver (40% and 
23%, respectively) (Fig. 2).
DISCUSSION
Studies have revealed that HCAs can be used for pre-
ventive and/or complementary therapeutic purposes 
in several diseases related to oxidative stress, such as 
atherosclerosis, inflammation, cancer and cardio-
vascular diseases [1]. However, there is no detailed 
information regarding the in vivo effect of HCA on 
phase I- and II-drug metabolizing enzymes that are 
important in drug-phytochemical interactions. Thus, 
the present study aimed to examine in detail the im-
pact of dietary HCAs on specific forms of P450 and 
Table 2. The effects of HCA on xenobiotic metabolizing and an-







min/mg prot.) 8.10± 1.89 6.26±2.03* 23  ↓
MROD (pmol resorufin/
min/mg prot.) 9.59± 3.75 8.39±2.23* 13  ↓
C3ND (nmol HCHO/
min/mg prot.) 0.46±0.06 0.40±0.02* 13  ↓
EmND (nmol HCHO/
min/mg prot.) 1.93±0.25 1.98±0.12 --
BPND (nmol HCHO/
min/mg prot.) 1.46±0.30 1.49±0.31 --
BROD (pmol resorufin/
min/mg prot.) 2.61±0.87 2.55±0.71 --
PROD (pmol resorufin/
min/mg prot.) 6.50±0.99 6.59±0.90 --
APND (nmol HCHO/
min/mg prot.) 0.339±0.03 0.343±0.01 --
ERND (nmol HCHO/
min/mg prot.) 0.106±0.02 0.110±0.02 --
DBFOD (nmol fluores-
cein/min/mg prot.) 6.60±0.12 5.55±0.27* 16 ↓
NQO1 (nmol/min/mg 
prot.) 187±11.35 254±16.32* 35 ↑
GST-CDNB (nmol/min/
mg prot.) 539±34.21 651±97.12* 20 ↑
GST-DCNB (nmol/min/
mg prot.) 13.89± 4.29 20.30±3.25* 46 ↑
GST- EA (nmol/min/mg 
prot.) 13.45±2.61 21.32±2.21* 59 ↑
CAT (nmol/min/mg 
prot.) 10.33±0.38 14.65±0.63* 42 ↑
GPX (nmol/min/mg 
prot.) 0.038±0.003 0.05±0.009* 32 ↑
*Significantly different from the respective control value P < 0.05
Table 1. Blood serum AST and ALT enzyme activities in control and HCA-treated rats.
  Aspartate   Alanine  
Aminotransferase Change Aminotransferase Change
  (AST) Unit/min/mg protein (Fold) (ALT) Unit/min/mg protein (Fold)
Control 1.55±0.09 -- 1.47±0.29 --
10 µM/kg HCA 1.57±0.11 -- 1.64±0.22 --
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also on selected phase II and antioxidant enzymes in 
Wistar rat. 
The range of the reported concentrations of HCA 
in fruits and vegetables varies between 0.03 and 14.4 
mg per 100 g food weight [37,38]. Ten µM of HCA 
was used throughout this study, based on our previous 
cell culture experiences with HCA and predictions 
[39] since there are no any related reports on HCA 
treatment of rat in the literature.
The activities of AST and ALT, alone or together, 
serve as indicators of hepatocellular damage in ro-
dents and non-rodents in non-clinical studies. They 
are precise markers for medication-prompted liver 
damage, and elevated activities of these markers in 
plasma point to cellular leakage and loss of functional 
integrity of the liver [40]. The activities of these mark-
ers in plasma were not changed in HCA-treated rats 
as compared to the control group. Hence, HCA, at 
the present measurements, can be utilized as a part of 
preventive or complementary medicine with wellbeing 
safety measures and within the scope of the methods 
employed in public health.
Among all cytochrome P450 isoforms, CYP1A 
holds priority due to its role in the metabolism of 
carcinogens, mutagens and environmental pollutants 
[41]. In this study, CYP1A1/CYP1A2-associated en-
zyme activities (EROD, MROD and C3ND) were de-
creased as a result of HCA treatment. Although HCA 
treatment led to a significant reduction in CYP1A1/
CYP1A2-associated enzyme activities, CYP1A1 pro-
tein and mRNA levels were unchanged by HCA treat-
ment. These data suggest that HCA directly inhibits 
these P450 enzymes without an alteration of its gene 
and protein expression. There are contradictory re-
sults between cell lines and animal studies regarding 
the HCA effect on CYP1A enzymes [11,23]. One of 
the reasons might be the differences in the metabolism 
of HCA in different species, as well as experimental 
conducts such as doses, treatments, etc. More studies 
are needed to provide clear evidence for this discrep-
ancy of its effects in different species.
Fig. 2. The expression levels of CYP1A1, CYP2B1, CYP2C6, CY-
P3A1, CYP19, GST-mu and GST-theta mRNAs in control and 
HCA-treated rats. Treatments were carried out as described in the 
Materials and Methods. Normalization of the real-time quantita-
tive RT-PCR data was carried out using housekeeping (GAPDH) 
genes. The bar graph represents the mean fold differences cal-
culated by 2DDCt method using normalized Ct values obtained 
from qRT-PCR analysis. Results are presented as the mean from 
three independent experiments performed in triplicate. * P|<0.05 
compared with the control group.
Fig. 1. (A) The expression levels of CYP1A1, CYP2B1, CYP2C6, 
CYP3A1 and CYP19 proteins in control and HCA-treated rats. 
Treatments were carried out as described in Materials and Meth-
ods. Representative immunoblot analysis of liver microsomal 
CYP1A1, CYP2B1, CYP2C6, CYP3A1 and CYP19 proteins in 
experimental groups, using rabbit anti-rat CYP1A1, CYP2B1, CY-
P2C6, CYP3A1 and CYP19 IgG. All lanes contain equal amounts 
of microsomal protein, i.e. 100 µg. (B) Semiquantitative analysis 
of Western blot data for all samples. Results are presented as the 
mean from three independent experiments and expressed as rela-
tive mean±standard deviation. Relative control values are taken 
as 100%. * P<0.05  compared with the control group.
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CYPs are an essential phase I drug-metabolizing 
enzyme framework and metabolize a mixed bag of 
medications [36]. The CYP3A subfamily comprises 
around 30% of the total P450 content in the human 
liver [42,43] and is included in the metabolism of 
more than half of the therapeutic ingredients [8]. 
The CYP2C subfamily is the second most abundant 
CYP in the human liver; it metabolizes a few regular 
medicines including ibuprofen, phenytoin and war-
farin [43,44]. In a similar way, the CYP2B subfamily 
metabolizes clinical medications, misused medica-
tions (e.g. nicotine), toxicants and endogenous neu-
rochemicals [45]. In humans, the CYP families exam-
ined in this study are in charge of 90% of the phase 
I-related metabolism of clinically utilized medications. 
HCA treatment did not change any CYP2B-associated 
EmND, BPND, BROD or PROD activities significant-
ly nor CYP2B mRNA and protein levels. Similarly, 
HCA treatment did not change CYP2C6-associated 
APND and CYP3A-associated ERND activities sig-
nificantly in the HCA-treated rats as compared to the 
control. These results showed that HCA did not cause 
any significant changes in the expression and activity 
levels of drug-metabolizing enzymes in rats. It could 
be speculated that HCA did not depict any interac-
tions with transcriptional regulators, such as the aryl 
hydrocarbon receptor, constitutive androstane recep-
tor, phenobarbital-responsive enhancer module and 
pregnane X receptor.
The aromatase enzyme, which transforms an-
drogen to estrogen, assumes a key role, especially in 
breast carcinogenesis [46]. CYP19-associated DBFOD 
activity was decreased as a result of HCA treatment. 
Additionally, CYP19 protein and mRNA levels were 
reduced with HCA treatment. Hence, the observed 
inhibition resulting from HCA treatment could be 
either transcriptional or translational and this remains 
to be elucidated. The results of this study suggest that 
HCA administration may be a suitable strategy for 
cancer chemoprevention of some cancers.
In this study, HCA treatment caused an increase 
in CAT, GPx, GSTs and NQO1 activities in rat liver. In 
addition, HCA caused significant (P<0.05) elevations 
in the levels of hepatic GST-mu and -theta mRNA, 
which handle the metabolism of numerous xenobi-
otics and play a major cellular antioxidant role. The 
redox-sensitive transcription factor nuclear factor 
erythroid 2-related factor 2 (Nrf2) plays a key role in 
the cellular defense against oxidative stress via tran-
scriptional upregulation of phase II defense enzymes 
and antioxidant stress proteins [47]. The induction of 
detoxification/antioxidant enzymes (GPx, GST, SOD, 
CAT, PRX) by Nrf2 is regulated via the antioxidant 
response element (ARE) in the promoter region of 
target genes [48]. Polyphenols activate the Nrf2/ARE 
pathway and increase the expression of detoxification/
antioxidant enzymes [48]. According to our results, 
the chemopreventive impact of HCA might be reflect-
ed in the activation of the Nrf2 pathway, stimulating 
the transcription of antioxidant enzymes.
Moreover, induction of GST-mu and -theta activ-
ity with HCA treatment is possibly associated with a 
potential chemoprotective ability of HCA, because 
GST-mu and GST- theta are GST isoforms that partic-
ipate in the metabolism of a wide range of chemicals, 
including carcinogens [49]. A lack of these enzyme ac-
tivities has been associated with cancer susceptibility 
[50]. Therefore, the results presented in this study may 
be of importance, given the possible use of HCA both 
as a potent anticancer agent as well as a chemopreven-
tive agent. It is known that dietary polyphenols may 
apply their anticancer impacts through various mech-
anisms, for example, elimination of cancer-causing 
factors, adjustment of cancer cell signaling, reinforce-
ment of antioxidant enzyme activities and the induc-
tion of apoptosis and cell-cycle arrest [5,51,52]. Some 
of these impacts may be connected to their indirect 
antioxidant activities. For instance, the induction of 
CAT, GPx, NQO1, GSTs and/or phase II enzymes by 
polyphenols could help the detoxification of cancer-
causing factors [41]. Therefore, the induction of these 
enzyme activities by HCA could be attributed to its 
cancer chemopreventive impact. 
In conclusion, the inhibition of CYP1A and 
CYP19 and the induction of CAT, GPx, GSTs and 
NQO1 enzymes reveal potential anticancer and che-
mopreventive roles for HCA, while the unchanged 
mRNA and protein levels of CYP2B, 2C and 3A in-
dicate that there is little or no drug interaction after 
HCA application.
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